Litigation Details for Abbott Diabetes Care Inc. v. Dexcom, Inc. (D. Del. 2021)
✉ Email this page to a colleague
Abbott Diabetes Care Inc. v. Dexcom, Inc. (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-07-01 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Kent A. Jordan |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,217,866 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Abbott Diabetes Care Inc. v. Dexcom, Inc.
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Abbott Diabetes Care Inc. v. Dexcom, Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-10-04 | 529 | Jury Instructions - Proposed | binding of EGF to the EGF receptor.” U.S. Patent 6,217,866. They now take the position that Figure 1(…the 338 patent, claim 3 of the 647 patent, claim 29 of the 649 patent, claim 10 of the 654 patent, claims…refer to each patent by the last three numbers of its patent number. For example, U.S. Patent No. 10,874,338…and 18 of the 443 patent, claim 2 of the 216 patent, and claim 24 of the 440 patent. These specific claims…(collectively, “the Asserted Patents”). A copy of each of these patents will be given to you. For your | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
